AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
230% more first-time investments, than exits
New positions opened: 241 | Existing positions closed: 73
22% more call options, than puts
Call options by funds: $3.71B | Put options by funds: $3.03B
18% more funds holding in top 10
Funds holding in top 10: 174 [Q2] → 206 (+32) [Q3]
10% more capital invested
Capital invested by funds: $234B [Q2] → $256B (+$22.5B) [Q3]
4% more funds holding
Funds holding: 3,301 [Q2] → 3,427 (+126) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 1,381 | Existing positions reduced: 1,378
3.38% less ownership
Funds ownership: 76.83% [Q2] → 73.44% (-3.38%) [Q3]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$191
11%
upside
Avg. target
$210
22%
upside
High target
$224
31%
upside
12 analyst ratings
10 positive
83%
2 neutral
17%
0 negative
0%
Truist Securities Srikripa Devarakonda 30% 1-year accuracy 10 / 33 met price target | 23%upside $211 | Buy Maintained | 8 Jan 2025 |
Piper Sandler Christopher Raymond 10% 1-year accuracy 3 / 30 met price target | 28%upside $220 | Overweight Maintained | 17 Dec 2024 |
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 11%upside $191 | Neutral Reinstated | 10 Dec 2024 |
Leerink Partners David Risinger 22% 1-year accuracy 2 / 9 met price target | 20%upside $206 | Outperform Upgraded | 22 Nov 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 19%upside $205 | Outperform Initiated | 15 Nov 2024 |
Financial journalist opinion
Based on 49 articles about ABBV published over the past 30 days
Positive
Seeking Alpha
1 day ago
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Positive
Seeking Alpha
3 days ago
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an unpredictable environment, focusing on companies with resilient business models can provide stability. Coca-Cola, AbbVie, and TC Energy stand out in this regard. These stocks offer defensive growth, attractive dividends, and strong fundamentals. They're well-positioned to navigate inflation while providing consistent income and long-term returns.
Positive
Zacks Investment Research
3 days ago
Why the Market Dipped But AbbVie (ABBV) Gained Today
In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.
Neutral
Seeking Alpha
5 days ago
AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) J.P. Morgan 43rd Annual Healthcare Conference January 15, 2025 11:15 AM ET Company Participants Rob Michael - Chief Executive Officer Scott Reents - Executive Vice President, Chief Financial Officer Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Conference Call Participants Chris Schott - J.P.
Negative
Reuters
5 days ago
AbbVie to 'commit less capital' towards psychiatric drugs, CEO says
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday.
Positive
Seeking Alpha
5 days ago
My Dividend Stock Portfolio: $10,000 In Dividends In 2024 - 97 Holdings With 13 Buys
In December, I invested around $1,200 primarily in Business Development Companies, boosting my annual dividend income by $131 with a full-year total of almost $1,700.
Neutral
Business Wire
5 days ago
Alzamend Neuro to Present at the Sequire Investor Summit
ATLANTA--(BUSINESS WIRE)---- $ABBV #ALZN--Alzamend Neuro to Present at Sequire Investor Summit; Company to Report Progress with Clinical Trials to be Initiated in 2025 and Expected Milestones.
Positive
Zacks Investment Research
6 days ago
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Positive
Zacks Investment Research
6 days ago
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Positive
The Motley Fool
6 days ago
2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio
Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and shareholder-friendly management teams.
Charts implemented using Lightweight Charts™